selected scholarly activity
-
chapters
-
conferences
- Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis. Journal of Crohn's and Colitis. 1863-1869. 2024
- The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn’s Disease. Inflammatory Bowel Diseases. 716-725. 2023
- Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. American Journal of Gastroenterology. 1106-1117. 2022
- Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Alimentary Pharmacology and Therapeutics. 1676-1682. 2020
- Effectiveness and safety of ustekinumab in patients with Crohn's disease: a real-world experience. Journal of Crohn's and Colitis. S426-S426. 2020
- Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study. Journal of Crohn's and Colitis. S110-S111. 2020
- Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial. Journal of Crohn's and Colitis. S465-S465. 2020
- Perceptions of faecal microbiota transplantation in patients with ulcerative colitis. Journal of Crohn's and Colitis. S335-S336. 2020
- Understanding Patients' Perceptions of Fecal Microbiota Transplant. American Journal of Gastroenterology. S5-S5. 2019
- Validation and evaluation of infliximab assay in IBD. Clinical Biochemistry. 94-94. 2019
- WEEK 2 ADALIMUMAB LEVEL PREDICTS SHORT-TERM CLINICAL REMISSION IN PATIENTS WITH IBD. Gastroenterology. S1142-S1142. 2019
- Surveillance colonoscopies in ulcerative colitis: does it make a difference?. Journal of Crohn's and Colitis. S70-S70. 2019
- P607 Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Journal of Crohn's and Colitis. S420-S420. 2019
- Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open. Journal of Crohn's and Colitis. S49-S49. 2018
- P047 HISTOLOGICAL AND ENDOSCOPIC HEALING AFTER QBECO TREATMENT IN AN OPEN-LABEL PHASE 2 STUDY IN PATIENTS WITH ULCERATIVE COLITIS. Inflammatory Bowel Diseases. S17-S17. 2018
- Canadian Study of Outcomes in Adalimumab Patients with Support for Adherence: Results from the COMPANION Study. Journal of Rheumatology. 936-937. 2017
- Impact of adalimumab's patient support program on clinical outcomes in inflammatory bowel diseases: results from the COMPANION study. Journal of Crohn's and Colitis. S438-S439. 2017
- Increasing treatment time on REMICADE (R) (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada. Journal of Crohn's and Colitis. S272-S273. 2017
- Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence - Results from the Companion Study. Arthritis & Rheumatology. 2016
- Canadian Study of Outcomes in Adalimumab Patients with Support for Adherence: Results from the COMPANION Study. American Journal of Gastroenterology. S446-S446. 2016
- Outcomes of Second- and Third-LineTumor Necrosis Factor-α Antagonists in Inflammatory Bowel Disease. American Journal of Gastroenterology. S428-S429. 2016
- Sa1085 Telephone vs. Clinic Follow-Up in the Management of Patients With Inflammatory Bowel Disease: A Nurse Practitioner Led Study. Gastroenterology. S235-S235. 2016
- Su1012 Canadian Patient and Caregiver Perspectives on Subsequent Entry Biologics/Biosimilars for Inflammatory Bowel Disease. Gastroenterology. S443-S444. 2016
- Anxiety and depression may lead to poor health-related quality of life in patients with inflammatory bowel disease. Journal of Crohn's and Colitis. S154-S154. 2016
- Canadian patient and caregiver perspectives on subsequent entry biologics/biosimilars for inflammatory bowel disease. Journal of Crohn's and Colitis. S319-S319. 2016
- Impact of high-dose vitamin D3 supplementation in treatment of Crohn's disease in remission: a randomised double-blind controlled study. Journal of Crohn's and Colitis. S429-S430. 2016
- Living with inflammatory bowel disease: results from focus group. Journal of Crohn's and Colitis. S499-S500. 2016
- P-064 Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohnʼs Disease in Remission. Inflammatory Bowel Diseases. S29-S30. 2016
- P-079 YI The Association Between Anxiety and Depression and Health Related Quality of Life in Patients with Inflammatory Bowel Disease (IBD). Inflammatory Bowel Diseases. S34-S34. 2016
- P-231 YI Patient Experience Living with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. S79-S79. 2016
- Telephone vs clinic follow-up in the management of patients with inflammatory bowel disease: a nurse practitioner-led study. Journal of Crohn's and Colitis. S495-S495. 2016
- Systematic Review and Meta-Analysis: Infliximab or Ciclosporin as Rescue Therapy in Patients with Severe Ulcerative Colitis Refractory to Steroids. Journal of Crohn's and Colitis. S313-S313. 2015
- Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology. S524-S524. 2014
- A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis.. Gastroenterology. S159-S159. 2014
- Anti-TNF alpha Therapies Are Safe During Pregnancy in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Gastroenterology. S582-S583. 2014
- Dermatological Complications of Anti-TNF-alpha Therapy in Crohn's Disease. Gastroenterology. S583-S583. 2014
- Investigating the microbiome pre and post fecal microbiota therapy from active ulcerative colitis patients in a randomized placebo controlled trial. Gastroenterology. S902-S902. 2014
- DOP040 Anti-TNF-α therapies are safe during pregnancy in patients with inflammatory bowel disease: a meta-analysis. Journal of Crohn's and Colitis. S34-S34. 2014
- P309 Transition experience from inpatient to ambulatory IBD care: Results of a pilot study. Journal of Crohn's and Colitis. S193-S194. 2014
- An Audit of Fecal Occult Blood Testing in Hospital Inpatients. American Journal of Gastroenterology. S495-S495. 2013
- Peri-operative Anti-TNFα Treatment and Post-operative Complications in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. American Journal of Gastroenterology. S551-S551. 2013
- Optimal Care in Crohn's Disease and Ulcerative Colitis: How Aligned With Patients' Needs and Expectations Are Health Care Providers?. Gastroenterology. S569-S569. 2013
- Psychosocial Characteristics of Patients With IBD: Experience From the Mcmaster Interdisciplinary Clinic. Gastroenterology. S651-S651. 2013
- Specific Crohn's Disease (CD) Associated Risk Alleles Are Associated With the Composition of the Intestinal Microbiota in Healthy First Degree Relatives (FDR) of CD Subjects. Gastroenterology. S57-S57. 2013
- The Relationship Between Common IBD-Associated Risk Alleles and Intestinal Permeability in a Cohort of Healthy First Degree Relatives of Individuals With Crohn's Disease. Gastroenterology. S835-S835. 2013
- Does Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease Impact Clinical Management? A Canadian Experience.. Inflammatory Bowel Diseases. S82-S83. 2012
- Validation and Comparison of Algorithms to Identify Adult-Onset Inflammatory Bowel Disease Patients From Within Health Administrative Data. Inflammatory Bowel Diseases. S30-S31. 2012
- Immediate Effects of Infliximab Infusion on Mood in Patients With Inflammatory Bowel Disease. Gastroenterology. S69-S69. 2012
- Interdisciplinary, prompt access IBD clinic: The hamilton health science experience. Inflammatory Bowel Diseases. S7-S7. 2011
- Lactose Hydrogen Breath Test as a Screening Test for Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology. S107-S108. 2009
- PG14 SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE. Value in Health. A346-A346. 2009
- Development and Validation of a Risk Score for Post Infectious Irritable Bowel Syndrome. Gastroenterology. A631-A631. 2009
- Fine Mapping of the Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome (PI-IBS) in the Walkerton Outbreak of Waterborne Gastroenteritis (GE). Gastroenterology. A155-A155. 2009
- Information Needs of Digestive Disease Patients: the Patient Education Needs Survey (PENS). Gastroenterology. A638-A638. 2009
- Post-Infective Dyspepsia Eight Years After the Walkerton Outbreak of Waterborne Gastroenteritis (GE). Gastroenterology. A59-A59. 2009
- Prognosis of Post-Infectious Irritable Bowel Syndrome (PI-IBS) Eight Years After the Walkerton Outbreak of Waterborne Gastroenteritis (GE). Gastroenterology. A629-A629. 2009
- Validation of Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome (IBS) in Patients with Sporadic IBS. Gastroenterology. A68-A68. 2009
- Post-infectious irritable bowel syndrome following water contamination. Kidney International, Supplement. S42-S43. 2009
- Genetic risk factors for post-infectious IBS in the walkerton outbreak of waterborne gastroenteritis. Gastroenterology. A122-A122. 2008
- PCN76 COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT. Value in Health. A346-A346. 2007
- Endoscopy Training for GI Trainees: The Impact of a 2-Day Introductory Training Course On Cognitive Knowledge. Gastrointestinal Endoscopy. AB312-AB312. 2007
- GI Endoscopy Training: Validation of a Computer-Based Endoscopy Simulator. Gastrointestinal Endoscopy. AB316-AB316. 2007
- Irritable bowel syndrome after intestinal infection: A systematic review and meta-analyses. Gastroenterology. A195-A195. 2007
- Prognosis of post-infectious irritable bowel syndrome (PI-IBS) six years after the Walkerton outbreak of waterborne gastroenteritis (GE). Gastroenterology. A66-A66. 2007
- Prognosis of post-infectious irritable bowel syndrome (PI-IBS) four years after the walkerton outbreak of waterborne gastroenteritis (GE). Gastroenterology. A52-A52. 2006
- Post-infectious irritable bowel syndrome (IBS) after the walkerton outbreak of waterborne gastroenteritis (GE).. Gastroenterology. A28-A28. 2005
- Prospective study of functional bowel disorders two years after a food borne outbreak of acute viral gastroenteritis. Gastroenterology. A332-A332. 2005
- Rectal 5ASA to maintain remission of distal ulcerative colitis (UC): a cochrane collaboration meta-analysis. Gastroenterology. A311-A312. 2005
- Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults – Update 2004. Canadian Journal of Gastroenterology and Hepatology. 15-35. 2005
- RANDOMIZED ACTIVE AND PLACEBO-CONTROLLED ENDOSCOPY STUDY EVALUATING A NOVEL PROTECTED FORMULATION OF ORAL ALENDRONATE. American Journal of Gastroenterology. S31-S31. 2004
- SC1 PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIES. Value in Health. 228-228. 2004
- Conjoint analysis (CA) of patient preferences for colorectal cancer (CRC) screening strategies. Gastroenterology. A608-A608. 2004
- Increased intestinal permeability (IP) in subjects with irritable bowel syndrome (IBS) two years after the Walkerton outbreak of waterborne gastroenteritis. Gastroenterology. A520-A520. 2004
- Photodynamic therapy (PDT) for Barrett's esophagus with high-grade dysplasia (BE+HGD): Cost-effectiveness model with probabilistic sensitivity analysis. Gastrointestinal Endoscopy. AB137-AB137. 2004
- Post infectious irritable bowel syndrome (PI-IBS) is transient following a foodborne outbreak of acute gastroenteritis attributed to a viral pathogen. Gastroenterology. A53-A53. 2004
- Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. ACP journal club. 843-843. 2003
- Home parenteral nutrition is cost-saving with low consumption of acute care resources. Gastroenterology. A431-A431. 2003
- Mood disorders and disease severity are the strongest predictors of health-related quality of life (HRQOL) in Crohn's disease and ulcerative colitis. Gastroenterology. A210-A210. 2003
- Variation in estimates of cost-effectiveness for colorectal cancer (CRC) screening: A systematic review. Gastroenterology. A620-A620. 2003
- Cytomegalovirus infection in steroid-refractory ulcerative colitis. American Journal of Gastroenterology. S257-S257. 2002
- Health care use increases in inflammatory bowel disease with severe disease and mood disturbance. Gastroenterology. A607-A607. 2002
- Home-care parenteral nutrition (PN) is cost-saving: Economic analysis of a home PN (HPN) service in Ontario, Canada.. American Journal of Clinical Nutrition. 429S-429S. 2002
- Funding the New Biologics – CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn’s Disease: Pearls and Pitfalls. Canadian Journal of Gastroenterology and Hepatology. 877-879. 2002
- Risedronate is associated with a lower incidence of gastric ulcers than alendronate: Results from two comparative studies. Journal of Rheumatology. 24-24. 2001
- Follow-up endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by H. pylori status. Bone. S222-S222. 2001
- 6-mercaptopurine (6-MP) is more cost-effective than 5-aminosalicylates (5-ASA) for post-operative prophylaxis in Crohn's disease (CD).. Gastroenterology. A622-A622. 2001
- CD23 Fc epsilon RII (low affinity IgE receptor) is expressed on human epithelial cells and upregulated by IL-4 and LPS. Gastroenterology. A188-A188. 2001
- COX-2 specific inhibition with MK-0663 120 mg q.d. over 4 weeks did not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg t.i.d.. Gastroenterology. A597-A597. 2001
- Carbon dioxide (CO2) vs room air (RA) insufflation for colonoscopy: A randomized double-blind controlled trial.. Gastrointestinal Endoscopy. AB76-AB76. 2001
- Incidence of gastric ulcers lower in postmenopausal women treated with risedronate than alendronate, regardless of H-pylori status. Gastrointestinal Endoscopy. AB202-AB202. 2001
- Mood disorders (MD) worsen health related quality of life (HRQOL) in inflammatory bowel disease (IBD). Gastroenterology. A451-A451. 2001
- Patient anxiety before endoscopy and barium radiography: A prospective comparison. Gastrointestinal Endoscopy. AB199-AB199. 2001
- Resource utilization for acute lower gastrointestinal bleeding (LGIB): The Ontario GI bleed study. Gastrointestinal Endoscopy. AB181-AB181. 2001
- Risedronate has significantly lower incidence of gastric ulcers compared to alendronate.. Journal of Bone and Mineral Research. S227-S227. 2000
- Increased intestinal permeability precedes Crohn's disease (CD) in a subject with familial risk.. Gastroenterology. A1356-A1356. 2000
- The severity of infectious gastroenteritis is not related to patient anxiety and depression. Gastroenterology. A375-A375. 2000
- C-13-urea breath test or H-pylori serology for the initial evaluation of young patients with ulcer-like dyspepsia: A decision analysis. Gastroenterology. A78-A78. 1999
- Cost-effectiveness of acid suppression versus misoprostol in the prevention of non-steroidal antliinflammatory drug (NSAID)-induced ulcers. Gastroenterology. A72-A72. 1999
- Small bowel meal with pneumocolon (SBMP) versus standard small bowel meal for the diagnosis of terminal ileal Crohn's disease: Incremental yield of double-contrast imaging. Gastroenterology. A771-A771. 1999
- Case cost and resource utilization for bleeding peptic ulcers: The Ontario GI bleed study.. Gastroenterology. A27-A27. 1998
- Determinants of case cost for non-variceal upper gastrointestinal hemorrhage at a Canadian community hospital.. Gastroenterology. A27-A27. 1998
- Resource utilization for non-variceal upper gastrointestinal hemorrhage (UGIH): Profile at a Canadian community hospital.. Gastroenterology. A383-A383. 1997
- Rectal corticosteroids (CS) are not the best therapy for distal ulcerative colitis (UC).. Gastroenterology. A957-A957. 1996
- GOB GAS ANALYZER SYSTEM. PROCEEDINGS OF THE 7TH US MINE VENTILATION SYMPOSIUM. 371-376. 1995
- TOPICAL AMINOSALICYLATE (ASA) THERAPY FOR DISTAL ULCERATIVE-COLITIS - A METAANALYSIS. Gastroenterology. A1037-A1037. 1994
-
journal articles
- Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study.. PharmacoEconomics - Open. 1-16. 2024
- Defining Endoscopic Remission in Crohn’s Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression. Clinical Gastroenterology and Hepatology. 22:1687-1696.e6. 2024
- The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study.. Journal of the Canadian Association of Gastroenterology. 7:290-298. 2024
- Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review. American Journal of Gastroenterology. 2024
- Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease. American Journal of Gastroenterology. 119:1355-1364. 2024
- Environmental Factors Associated with Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial Project. Clinical Gastroenterology and Hepatology. 22:1889-1897.e12. 2024
- Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index. Inflammatory Bowel Diseases. 30:370-381. 2024
- Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy. Inflammatory Bowel Diseases. 30:311-313. 2024
- Understanding Predictors of Crohn's Disease: Determinants of Altered Barrier Function in Pre-Disease Phase of Crohn's Disease. Journal of the Canadian Association of Gastroenterology. 7:68-77. 2024
- A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design. Clinical Oncology. 36:e11-e19. 2024
- Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders. Clinical Gastroenterology and Hepatology. 21:3387-3396.e1. 2023
- Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn’s Disease. Journal of Clinical Gastroenterology. 57:913-919. 2023
- Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis. European Journal of Gastroenterology and Hepatology. 35:1131-1136. 2023
- Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease. Advances in Therapy. 40:4421-4439. 2023
- Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study. Clinical Gastroenterology and Hepatology. 21:2649-2659.e16. 2023
- Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives. Gastroenterology. 165:670-681. 2023
- Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease. Inflammatory Bowel Diseases. 29:1390-1398. 2023
- Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis. Inflammatory Bowel Diseases. 29:1263-1271. 2023
- Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY study. Journal of Crohn's and Colitis. 17:1114-1121. 2023
- Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease. Inflammatory Bowel Diseases. 29:1015-1023. 2023
- Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study. Digestive Diseases and Sciences. 68:2635-2646. 2023
- Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease. Inflammatory Bowel Diseases. 29:875-882. 2023
- Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission. Digestive Diseases and Sciences. 68:2658-2666. 2023
- Healthcare systems data in the context of clinical trials – A comparison of cardiovascular data from a clinical trial dataset with routinely collected data. Contemporary Clinical Trials. 128:107162-107162. 2023
- Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis. Gastroenterology. 164:619-629. 2023
- Increasing frailty is associated with higher prevalence and reduced recognition of delirium in older hospitalised inpatients: results of a multi-centre study. European Geriatric Medicine. 14:325-332. 2023
- Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 21:1050-1060.e9. 2023
- End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis. Scandinavian Journal of Gastroenterology, Supplement. 58:7-14. 2023
- Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study. American Journal of Gastroenterology. 118:121-128. 2023
- Pilot study of an elimination diet in adults with mild to moderate Crohn’s disease. European Journal of Gastroenterology and Hepatology. 34:1210-1219. 2022
- Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn’s Disease. Gastroenterology. 163:1364-1376.e10. 2022
- Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory Bowel Diseases. 28:1555-1564. 2022
- Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response. Journal of the Canadian Association of Gastroenterology. 5:208-213. 2022
- Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology. 56:794-797. 2022
- Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation. Gastroenterology. 163:685-698. 2022
- Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis. 16:1011-1019. 2022
- Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease. Clinical Gastroenterology and Hepatology. 20:1579-1587.e2. 2022
- Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20:1588-1597.e3. 2022
- Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics - Open. 6:519-537. 2022
- Canadian Consensus Statements on the Transition of Adolescents and Young Adults with Inflammatory Bowel Disease from Pediatric to Adult Care: A Collaborative Initiative Between the Canadian IBD Transition Network and Crohn’s and Colitis Canada. Journal of the Canadian Association of Gastroenterology. 5:105-115. 2022
- Ozanimod for the Treatment of Ulcerative Colitis. Gastroenterology. 162:2104-2106. 2022
- Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD). Gut. 71:1078-1087. 2022
- Reply. Clinical Gastroenterology and Hepatology. 20:e1510-e1511. 2022
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet. 399:2200-2211. 2022
- Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease. Journal of Crohn's and Colitis. 16:616-624. 2022
- Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20:1095-1104.e9. 2022
- Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. Digestive Diseases and Sciences. 67:1850-1857. 2022
- Reply. Clinical Gastroenterology and Hepatology. 20:e1216-e1217. 2022
- Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease. Alimentary Pharmacology and Therapeutics. 55:1151-1159. 2022
-
Editorial: is it not just
PRO s, but the most important individualPRO , that really matters in Crohn’s disease? Authors’ reply. Alimentary Pharmacology and Therapeutics. 55:1040-1041. 2022 - Reduction in Anxiety and Depression Scores Associated with Improvement in Quality of Life in Patients with Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology. 5:12-17. 2022
- Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis: A Qualitative Assessment of Patient Perceptions and Experiences. Journal of the Canadian Association of Gastroenterology. 4:e120-e129. 2021
- Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology. 4:S10-S19. 2021
- Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. Journal of the Canadian Association of Gastroenterology. 4:S1-S9. 2021
- Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology. 4:S61-S67. 2021
- Disruption of autophagy by increased 5-HT alters gut microbiota and enhances susceptibility to experimental colitis and Crohn’s disease. Science Advances. 7:eabi6442. 2021
- Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis. Journal of Crohn's and Colitis. 15:1649-1657. 2021
- Declining Use of Corticosteroids for Crohn’s Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial. Journal of the Canadian Association of Gastroenterology. 4:214-221. 2021
- Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti‐tumor necrosis factor experienced Crohn's disease patients: A propensity‐score matched cohort analysis. Journal of Gastroenterology and Hepatology. 36:2803-2812. 2021
- Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study. Gastroenterology. 161:1333-1335.e1. 2021
- Systematic review and meta‐analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology. 36:2640-2648. 2021
- Stability of diagnostic rate in a cohort of 38,813 colorectal polyp specimens and implications for histomorphology and statistical process control. Scientific Reports. 11:16942. 2021
- Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines. Gastroenterology. 161:669-680.e0. 2021
- Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines. Journal of the Canadian Association of Gastroenterology. 161:681-700. 2021
- Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines. Journal of the Canadian Association of Gastroenterology. 4:e59-e71. 2021
- Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. The BMJ. 374:n1554-n1554. 2021
- Counselling patients for return to work on immunosuppression: practices of Canadian specialists during the COVID-19 pandemic. Clinical and Experimental Rheumatology. 39:874-878. 2021
- End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn’s Disease. Journal of Crohn's and Colitis. 15:1114-1119. 2021
- The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies. United European Gastroenterology Journal. 9:581-589. 2021
- Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial. Inflammatory Bowel Diseases. 27:848-854. 2021
- Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results. Journal of the Canadian Association of Gastroenterology. 4:84-90. 2021
- Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn’s Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. Journal of Crohn's and Colitis. 15:462-470. 2021
- Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn’s Recurrence: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 19:451-462. 2021
- A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease. Journal of the Canadian Association of Gastroenterology. 4:48-48. 2021
- Clinical Management of the Microbiome in Irritable Bowel Syndrome. Journal of the Canadian Association of Gastroenterology. 4:36-43. 2021
- Erratum. Journal of the Canadian Association of Gastroenterology. 4:50-50. 2021
- Impact of Digital Health Monitoring in the Management of Inflammatory Bowel Disease. Journal of Medical Systems. 45:23. 2021
- Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. The Lancet. 397:581-591. 2021
- Patients’ Experiences and Challenges in Living with Inflammatory Bowel Disease: A Qualitative Approach. Clinical and Experimental Gastroenterology. Volume 14:123-131. 2021
- Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn’s disease subjects. BMC Medical Genomics. 21:204. 2020
- Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease. Gastroenterology. 159:2092-2100.e5. 2020
- Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. Intestinal Research. 18:430-437. 2020
- Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. American Journal of Gastroenterology. 115:1236-1245. 2020
- Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies. Clinical Gastroenterology and Hepatology. 18:2143-2146. 2020
- Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, Supplement. 55:800-805. 2020
- Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Alimentary Pharmacology and Therapeutics. 51:997-998. 2020
- ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. Journal of Crohn's and Colitis. 14:155-168. 2020
- Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Clinical Gastroenterology and Hepatology. 18:24-41.e1. 2020
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 14:4-22. 2020
- Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology and Therapeutics. 51:271-280. 2020
- Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. ACP journal club. 171:805-805. 2019
- Colorectal cancer screening for patients with a family history of colorectal cancer or adenomas.. Canadian Family Physician. 65:784-789. 2019
- Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn’s Disease. Inflammatory Bowel Diseases. 25:1796-1804. 2019
- Anxiety, Depression and Quality of Life Improve After One Month and Three Months of Home Parenteral Nutrition: A Pilot Study in a Canadian Population. Journal of the Canadian Association of Gastroenterology. 2:178-185. 2019
- Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary. Journal of the Canadian Association of Gastroenterology. 2:149-152. 2019
- Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Clinical Gastroenterology and Hepatology. 17:1680-1713. 2019
- Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Gastroenterology. 157:320-348. 2019
- Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Journal of the Canadian Association of Gastroenterology. 2:e1-e34. 2019
- Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease. Journal of the Canadian Association of Gastroenterology. 2:e35-e63. 2019
- Characterization of Serotonin Signaling Components in Patients with Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology. 2:132-140. 2019
- Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. Journal of Rheumatology. 46:751-754. 2019
- Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, Supplement. 54:712-717. 2019
- Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus. Inflammatory Bowel Diseases. 25:1-13. 2019
- Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. Frontiers in Medicine. 6:170. 2019
- Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. Medical and Surgical Dermatology. 23:50-74. 2019
- Fecal transplantation for recurrent or refractory Clostridium difficile diarrhea. Cochrane Database of Systematic Reviews. 2018. 2018
- Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology. 1:141-154. 2018
- Impact of Adalimumab Patient Support Program’s Care Coach Calls on Clinical Outcomes in Patients with Crohn’s Disease in Canada: An Observational Retrospective Cohort Study. Journal of the Canadian Association of Gastroenterology. 1:191-198. 2018
- In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not. ACP journal club. 169:JC54-JC54. 2018
- Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus. Gastroenterology. 155:1325-1347.e3. 2018
- Post‐infectious IBS: Defining its clinical features and prognosis using an internet‐based survey. United European Gastroenterology Journal. 6:1245-1253. 2018
- Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study. Clinical Therapeutics. 40:1024-1032. 2018
- 1068 - Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals with a Family History of Nonhereditary Colorectal Cancer or Adenoma: the Canadian Association of Gastroenterology Banff Consensus. Gastroenterology. 154:S-205. 2018
- Journal of the Canadian Association of Gastroenterology. Journal of the Canadian Association of Gastroenterology. 1:1-1. 2018
- Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study. Clinical Therapeutics. 40:415-429.e6. 2018
- Identifying Needs in Young Adults With Inflammatory Bowel Disease. Gastroenterology Nursing. 41:19-28. 2018
- Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. Frontiers in Immunology. 9:2211. 2018
- Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database. Patient Preference and Adherence. Volume 12:1805-1814. 2018
- Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. Cochrane Database of Systematic Reviews. 2017:CD009839. 2017
- Development of the IBD Disk. Inflammatory Bowel Diseases. 23:333-340. 2017
- Impact of High-Dose Vitamin D3 Supplementation in Patients with Crohn’s Disease in Remission: A Pilot Randomized Double-Blind Controlled Study. Digestive Diseases and Sciences. 62:448-455. 2017
- Reply. Gastroenterology. 152:303-304. 2017
- Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents. Canadian Journal of Gastroenterology and Hepatology. 2017:1-11. 2017
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. New England Journal of Medicine. 375:1946-1960. 2016
- Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open. 6:e010983-e010983. 2016
- Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. Journal of Crohn's and Colitis. 10:925-933. 2016
- The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 151:51-69.e14. 2016
- Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. American Journal of Gastroenterology. 111:477-491. 2016
- The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 150:734-757.e1. 2016
- Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. Journal of Blood Medicine. Volume 7:239-253. 2016
- Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial. Journal of General Internal Medicine. 31:68-76. 2016
- New Applications for Traditional Drugs in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 21:2948-2957. 2015
- European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. Journal of Crohn's and Colitis. 9:945-965. 2015
- Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 149:102-109.e6. 2015
- Systematic Review. Inflammatory Bowel Diseases. 21:1683-1694. 2015
- Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. Gastroenterology. 148:1035-1058.e3. 2015
- The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. Clinical Gastroenterology and Hepatology. 13:928-935.e2. 2015
- Intra-Operative Tissue Oxygen Tension Is Increased by Local Insufflation of Humidified-Warm CO2 during Open Abdominal Surgery in a Rat Model. PLoS ONE. 10:e0122838-e0122838. 2015
- Patients and Practice Guidelines: Keeping Eyes on the Horizon. Canadian Journal of Gastroenterology and Hepatology. 29:290-290. 2015
- The journey Continues. Canadian Journal of Gastroenterology and Hepatology. 29:175-175. 2015
- Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 20:1862-1869. 2014
- Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. Journal of Clinical Epidemiology. 67:887-896. 2014
- Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. Journal of Crohn's and Colitis. 8:571-581. 2014
- The Origins of Irritable Bowel Syndrome: Experience of a Lifetime. Gastroenterology. 147:18-20. 2014
- Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. Gastroenterology. 146:835-848.e6. 2014
- Canadian Association of Gastroenterology Position Statement Regarding the Use of Thiopurines for the Treatment of Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology. 28:371-372. 2014
- Canadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy. Canadian Journal of Gastroenterology and Hepatology. 28:66-68. 2014
- Fecal Occult Blood Testing as a Diagnostic Test in Symptomatic Patients is not Useful: A Retrospective Chart Review. Canadian Journal of Gastroenterology and Hepatology. 28:421-426. 2014
- Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics. 38:447-459. 2013
- Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests?. Journal of Gastroenterology and Hepatology. 28:931-936. 2013
-
Meta‐analysis: peri‐operative anti‐
TNF α treatment and post‐operative complications in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics. 37:1057-1064. 2013 - Meta‐analysis: colonoscopic post‐polypectomy bleeding in patients on continued clopidogrel therapy. Alimentary Pharmacology and Therapeutics. 37:947-952. 2013
- Bell's palsy in a patient receiving adalimumab for Crohn's disease. Journal of Crohn's and Colitis. 7:e115-e115. 2013
- Resource utilization during pediatric to adult transfer of care in IBD. Journal of Crohn's and Colitis. 7:e55-e60. 2013
- The Burden of Celiac Disease in Canada: More Work Needed to Lighten the Load. Canadian Journal of Gastroenterology and Hepatology. 27:448-448. 2013
- An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening. BMC Medical Research Methodology. 12:15. 2012
- Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. 11:CD004118. 2012
- Are Patients with Inflammatory Bowel Disease at Increased Risk of Coronary Artery Disease?. American Journal of Medicine. 125:956-962. 2012
- Clustering and stability of functional lower gastrointestinal symptom after enteric infection. Neurogastroenterology and Motility. 24:546-546. 2012
- Fecal Transplant for Clostridium difficile —Reply. JAMA Internal Medicine. 172:825-826. 2012
- Management of inflammatory bowel disease with vitamin D: Beyond bone health. Journal of Crohn's and Colitis. 6:397-404. 2012
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 61:535-542. 2012
- Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology. 10:234-239. 2012
- Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. Journal of Crohn's and Colitis. 6:77-85. 2012
- Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements. American Journal of Gastroenterology. 107:179-194. 2012
- Fecal Transplant via Retention Enema for Refractory or Recurrent <emph type="ital">Clostridium difficile</emph> Infection. JAMA Internal Medicine. 172:191-191. 2012
- An Audit of Influenza Vaccination Status in Adults with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology. 26:593-596. 2012
- Safety of Esophagogastroduodenoscopy within 30 Days of Myocardial Infarction: A Retrospective Cohort Study from a Canadian Tertiary Centre. Canadian Journal of Gastroenterology and Hepatology. 26:151-154. 2012
- Measurement of emotional/psychological child maltreatment: A review. Child Abuse and Neglect. 35:767-782. 2011
- A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-year outcomes. Surgical Endoscopy. 25:2547-2554. 2011
- Corrigendum: Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 106:1014-1014. 2011
- Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 106:661-673. 2011
- Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 106:617-629. 2011
- Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 106:601-616. 2011
- Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 106:590-599. 2011
- Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease: A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation. Value in Health. 14:263-273. 2011
- Reply. Gastroenterology. 140:728-729. 2011
- Should Albumin Be Used in All Patients with Spontaneous Bacterial Peritonitis?. Canadian Journal of Gastroenterology and Hepatology. 25:373-376. 2011
- Role of probiotics in management of diverticular disease. Journal of Gastroenterology and Hepatology. 25:1827-1830. 2010
- IgG4-Related Sclerosing Disease: A Novel Mimic of Inflammatory Bowel Disease. Digestive Diseases and Sciences. 55:3047-3051. 2010
- Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 59:605-611. 2010
- Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study. Gastroenterology. 138:1727-1736. 2010
- An Outbreak of Acute Bacterial Gastroenteritis Is Associated With an Increased Incidence of Irritable Bowel Syndrome in Children. American Journal of Gastroenterology. 105:933-939. 2010
- Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis. Gastroenterology. 138:1502-1513. 2010
- Patient outcomes after anti TNF-α drugs for Crohn’s disease. Expert Review of Pharmacoeconomics and Outcomes Research. 10:163-175. 2010
- Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. CD004115. 2010
- Should My Patient with Inflammatory Bowel Disease on Immunosuppressive Therapy be Vaccinated against Influenza Virus?. Canadian Journal of Gastroenterology and Hepatology. 24:121-125. 2010
- How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated‐choice survey. Health Economics. 18:1420-1439. 2009
- Development and Validation of a Risk Score for Post-Infectious Irritable Bowel Syndrome. American Journal of Gastroenterology. 104:2267-2274. 2009
- Non-Variceal Upper GI Bleeding in Patients Already Hospitalized for Another Condition. American Journal of Gastroenterology. 104:330-339. 2009
- Adherence to Guidelines for Surveillance Colonoscopy in Patients with Ulcerative Colitis at a Canadian Quaternary Care Hospital. Canadian Journal of Gastroenterology and Hepatology. 23:613-617. 2009
- Assessing the Educational Needs of Canadian Gastroenterologists and Gastroenterology Nurses: Challenges to Optimal Care in Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology. 23:805-810. 2009
- Myocardial Infarction, Peptic Ulcer and Acetylsalicylic Acid: Of Good and Evil. Canadian Journal of Gastroenterology and Hepatology. 23:618-618. 2009
- Post-infectious irritable bowel syndrome. World Journal of Gastroenterology. 15:3591-3591. 2009
- Who is Identified by Screening for Intimate Partner Violence?. Women's Health Issues. 18:423-432. 2008
- Are there epidemiological differences between crohnʼs disease and ulcerative colitis?. Inflammatory Bowel Diseases. 14:S1-S1. 2008
- Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn's disease. BMJ Evidence-Based Medicine. 13:115-115. 2008
- Review: Azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn disease. ACP journal club. 148:JC4-JC4. 2008
- Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn disease.. ACP journal club. 148:9. 2008
- Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology. 22:261-272. 2008
- The Irritable Infection. Canadian Journal of Gastroenterology and Hepatology. 22:669-670. 2008
- Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey. Value in Health. 10:415-430. 2007
- Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression. American Journal of Gastroenterology. 102:2047-2056. 2007
- Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome. Alimentary Pharmacology and Therapeutics. 26:535-544. 2007
- Postinfectious Irritable Bowel Syndrome After a Food-Borne Outbreak of Acute Gastroenteritis Attributed to a Viral Pathogen. Clinical Gastroenterology and Hepatology. 5:457-460. 2007
- Photodynamic Therapy for Barrett’s Esophagus with High-Grade Dysplasia: A Cost-Effectiveness Analysis. Canadian Journal of Gastroenterology and Hepatology. 21:217-222. 2007
- A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Versus Proton Pump Inhibitors for Treatment of Patients With Chronic Gastroesophageal Reflux Disease: One-Year Follow-Up. Surgical Innovation. 13:238-249. 2006
- Incidence and Epidemiology of Irritable Bowel Syndrome After a Large Waterborne Outbreak of Bacterial Dysentery. Gastroenterology. 131:445-450. 2006
- Randomized Active and Placebo-Controlled Endoscopy Study of a Novel Protected Formulation of Oral Alendronate. Digestive Diseases and Sciences. 51:864-868. 2006
- The Incidence of Irritable Bowel Syndrome Among Community Subjects With Previous Acute Enteric Infection. Digestive Diseases and Sciences. 51:1026-1032. 2006
- A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water. Journal of Clinical Epidemiology. 59:421-428. 2006
- Finding Inflammatory Bowel Disease Genes Will Not Lead to a Cure. Canadian Journal of Gastroenterology and Hepatology. 20:643-644. 2006
- Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health. Inflammatory Bowel Diseases. 12:38-46. 2006
- Reporting Ileocolonoscopy in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology. 20:399-400. 2006
- Validation of the Rockall scoring system for outcomes from non-variceal upper gastrointestinal bleeding in a Canadian setting. World Journal of Gastroenterology. 12:7779-7779. 2006
- CD23-Mediated IgE Transport Across Human Intestinal Epithelium: Inhibition by Blocking Sites of Translation or Binding. Gastroenterology. 129:928-940. 2005
- Response to "Potentially Flawed Interpretation of Data by Andriulli et al.". American Journal of Gastroenterology. 100:2133-2133. 2005
- Economic Analysis of Home vs Hospital‐Based Parenteral Nutrition in Ontario, Canada. Journal of Parenteral and Enteral Nutrition. 29:266-269. 2005
- Long-term Health Sequelae Following E.coli and Campylobacter Contamination of Municipal Water. Canadian Journal of Public Health. 96:125-130. 2005
- A Sampling of Canadian Practice in Managing Nonvariceal Upper Gastrointestinal Bleeding before Recent Guideline Publication: Is there Room for Improvement?. Canadian Journal of Gastroenterology and Hepatology. 19:487-495. 2005
- Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Alimentary Pharmacology and Therapeutics. 20:1317-1322. 2004
- Should Health Professionals Screen All Women for Domestic Violence?. PLoS Medicine. 1:e4-e4. 2004
- Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. ACP journal club. 141:78-78. 2004
- Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. ACP journal club. 141:80-80. 2004
- Prospective Comparison of Small Bowel Meal with Pneumocolon versus Ileo-Colonoscopy for the Diagnosis of Ileal Crohn's Disease. American Journal of Gastroenterology. 99:1321-1329. 2004
- A distinctive case of dysphagia.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 170:42. 2004
- A Canadian Clinical Practice Algorithm for the Management of Patients with Non-Variceal Upper Gastrointestinal Bleeding. Canadian Journal of Gastroenterology and Hepatology. 18:605-609. 2004
- Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease. Canadian Journal of Gastroenterology and Hepatology. 18:503-508. 2004
- Talk Is Cheap: The Impact of Consultation. Commentary on the Article. Canadian Journal of Gastroenterology and Hepatology. 18:181-182. 2004
- Restricted access for PPIs not a panacea - Response. CANADIAN MEDICAL ASSOCIATION JOURNAL. 167:1102-+. 2002
- Restricted access for PPIs not a panacea.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 167:1102. 2002
- A Semiquantitative Stool Antigen Test for Helicobacter pylori. Journal of Clinical Gastroenterology. 35:369-370. 2002
- 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.. Journal of Rheumatology. 29:1965-1974. 2002
- Re: Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol 2002; 16 : 231-40 - Response. Canadian Journal of Gastroenterology and Hepatology. 16:651-652. 2002
- Re: Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of the gastroprotective agents.. Canadian Journal of Gastroenterology and Hepatology. 16:651. 2002
- Minimizing postcolonoscopy abdominal pain by using CO insufflation: A prospective, randomized, double blind, controlled trial evaluating a new commercially available CO delivery system. Gastrointestinal Endoscopy. 56:190-194. 2002
- Minimizing postcolonoscopy abdominal pain by using CO2 insufflation: A prospective, randomized, double blind, controlled trial evaluating a new commercially available CO2 delivery system. Gastrointestinal Endoscopy. 56:190-194. 2002
- Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. Value in Health. 5:312-328. 2002
- Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 166:1655-1662. 2002
- The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opinion on Drug Safety. 1:71-78. 2002
- Recommendations for the Appropriate Use of Anti-Inflammatory Drugs in the Era of the Coxibs: Defining the Role of Gastroprotective Agents. Canadian Journal of Gastroenterology and Hepatology. 16:231-240. 2002
- Resource Utilization for Acute Lower Gastrointestinal Hemorrhage: The Ontario GI Bleed Study. Canadian Journal of Gastroenterology and Hepatology. 16:677-682. 2002
- Use and misuse of cost-effectiveness terminology in the gastroenterology literature: a systematic review. American Journal of Gastroenterology. 97:172-179. 2002
- Use and misuse of cost-effectiveness terminology in the gastroenterology literature: a systematic review. American Journal of Gastroenterology. 97:172-179. 2002
- LDP-02 (Millenium).. Current Opinion in Investigational Drugs. 2:502-504. 2001
- Epidemiological Aspects of Irritable Bowel Syndrome in Europe and North America. Digestion. 64:200-204. 2001
- Incremental Cost-Effectiveness Analysis Comparing Rofecoxib with Nonselective NSAIDs in Osteoarthritis. PharmacoEconomics (Auckland). 19:1039-1049. 2001
- Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology. 119:1740-1744. 2000
- A randomized controlled trial to assess alendronate‐associated injury of the upper gastrointestinal tract. Alimentary Pharmacology and Therapeutics. 14:1451-1457. 2000
- Putting Rectal 5-Aminosalicylic Acid in Its Place: The Role in Distal Ulcerative Colitis. American Journal of Gastroenterology. 95:1628-1636. 2000
- Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. American Journal of Gastroenterology. 95:1628-1636. 2000
- A Critical Approach to Clinical Practice Guidelines. Canadian Journal of Gastroenterology and Hepatology. 14:505-509. 2000
- Obscure Gastrointestinal Bleeding: An Approach to Management. Canadian Journal of Gastroenterology and Hepatology. 14:111-118. 2000
- Test-and-Treat Strategies forHelicobacter pyloriin Uninvestigated Dyspepsia: A Canadian Economic Anaylsis. Canadian Journal of Gastroenterology and Hepatology. 14:379-388. 2000
- Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Critical Care Medicine. 27:2812-2817. 1999
- Marked Elevation of Serum Transaminases May Be Associated With Ovarian Hyperstimulation Syndrome. American Journal of Gastroenterology. 94:3373-3373. 1999
- Ilodecakin. Schering-Plough Corp.. IDrugs: the Investigational Drugs Journal. 2:1045-1058. 1999
- Demographic Predictors of Resource Utilization for Bleeding Peptic Ulcer Disease: The Ontario GI Bleed Study. Journal of Clinical Gastroenterology. 29:165-170. 1999
- Prediction of Resource Utilization and Case Cost for Acute Nonvariceal Upper Gastrointestinal Hemorrhage at A Canadian Community Hospital. American Journal of Gastroenterology. 94:1841-1846. 1999
- Correspondence. American Journal of Gastroenterology. 94:1108-1109. 1999
- Cost and Cost-Effectiveness: Consistent Terminology Is Needed. American Journal of Gastroenterology. 94:1108-1109. 1999
- Lymphocytic and collagenous colitis: Medical management. Current Treatment Options in Gastroenterology. 2:127-133. 1999
- Terminal Ileal Imaging With Ileoscopy Versus Small-Bowel Meal With Pneumocolon. Journal of Clinical Gastroenterology. 27:217-222. 1998
- A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation. New England Journal of Medicine. 338:791-797. 1998
- Ketotifen Treatment of Active Colitis in Patients with 5‐Aminosalicylate Intolerance. Canadian Journal of Gastroenterology and Hepatology. 12:273-275. 1998
- Omeprazole for Refractory Gastroesophageal Reflux Disease during Pregnancy and Lactation. Canadian Journal of Gastroenterology and Hepatology. 12:225-227. 1998
- Therapeutic placebo in ulcerative colitis: fact or fiction?. Gastroenterology. 113:2021-2022. 1997
- Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.. Gut. 40:775-781. 1997
- Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities: a promising alternative. European Journal of Gastroenterology and Hepatology. 9:521-525. 1997
- Successful Therapy of Refractory Erythema Nodosum Associated with Crohn's Disease Using Potassium Iodide. Canadian Journal of Gastroenterology and Hepatology. 11:501-502. 1997
- Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis. Alimentary Pharmacology and Therapeutics. 9:293-300. 1995
- Xylem sap flow, growth and flower production of cultivated Geraldton wax with different vigour under semi-arid conditions. Crop and Pasture Science. 46:581-581. 1995